The fixed-dose combination of perindopril and amlodipine improved the CCS class and exercise capacity in patients with SCAD after 6  months of treatment. The fixed-dose combination of perindopril and amlodipine can have favorable effects on the cardiovascular system, not only by its BP-lowering effect and its effect on vascular resistance but also t..."> The fixed-dose combination of perindopril and amlodipine improved the CCS class and exercise capacity in patients with SCAD after 6  months of treatment. The fixed-dose combination of perindopril and amlodipine can have favorable effects on the cardiovascular system, not only by its BP-lowering effect and its effect on vascular resistance but also t..." /> The fixed-dose combination of perindopril and amlodipine improved the CCS class and exercise capacity in patients with SCAD after 6  months of treatment. The fixed-dose combination of perindopril and amlodipine can have favorable effects on the cardiovascular system, not only by its BP-lowering effect and its effect on vascular resistance but also t..." />

Short-Term Cardioprotective Effects of the Original Perindopril/Amlodipine Fixed-Dose Combination in Patients with Stable Coronary Artery Disease: Results of the PAPA-CAD Study

Conclusion < /h3 > < p class= " a-plus-plus " > The fixed-dose combination of perindopril and amlodipine improved the CCS class and exercise capacity in patients with SCAD after 6  months of treatment. The fixed-dose combination of perindopril and amlodipine can have favorable effects on the cardiovascular system, not only by its BP-lowering effect and its effect on vascular resistance but also through its direct cardiovascular protective effects. < /p > < /span > < span class= " a-plus-plus abstract-section id-a-sec5 " > < h3 class= " a-plus-plus " > Funding < /h3 > < p class= " a-plus-plus " > Egis Pharmaceuticals. < /p > < /span > < span class= " a-plus-plus abstract-section id-a-sec6 " > < h3 class= " a-plus-plus " > Trial registration < /h3 > < p class= " a-plus-plus " > 21938-1/2011-EKU (698/PI/11.) < /p > < /span >
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research